InsiderTradr

Panacea Biotec Limited (PANACEABIO.BO)

BSE · INR · Healthcare · Biotechnology

₹320.90 (+4.34%) as of

Key statistics

Market cap
19.61B
EPS (TTM)
-1.17
Dividend yield
0.00%
52-week range
293.10 – 647.50
Beta
0.25
Revenue (TTM)
6.73B
Profit margin
-1.06%
Volume
1.38k

About Panacea Biotec Limited

Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. The company operates through Vaccines and Pharmaceutical Formulations & Nutrition segments. Its product portfolio includes prescription products in various therapeutic areas, such as diabetes, gastro-intestinal care, nephrology, oncology, orthopedics, pain management, and fever; cold and cough; and betacoronavirus, SARS-CoV-2, typhoid conjugate, pneumococcal conjugate, tetravalent dengue, and Mpox, etc. The company also offers health supplement products; and nutrition products under the ChilRun full, ChilRun 7+, and ChillRun No Sucrose brands. In addition, it engages in the real estate business. It exports its products to approximately 50 countries. It has collaboration agreements with the Russian Direct Investment Fund for producing Covid-19 vaccine, and Sputnik-V; and the Indian Council of Medical Research for clinical trials of DengiAll vaccine. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.

Sector
Healthcare
Industry
Biotechnology
Headquarters
New Delhi, India
Employees
2,102

panaceabiotec.com

Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.

Related stocks